Baerenkraft Therapeutics is redefining the conventional drug development model by deploying a flexible, capital-efficient, and partner-centric strategy designed for the realities of today’s global therapeutic landscape.
PipelineWe specialize in supporting early-phase clinical development across high-impact therapeutic areas. Our experience spans complex disease landscapes where precision, speed, and adaptability are critical. By focusing on immunology, inflammation, and metabolic disorders, we help bring novel treatments to patients faster.
About
Our work in immunology addresses complex disorders with high unmet need. We are advancing select candidates with strong scientific and translational rationale.
By understanding the role of chronic inflammation, we navigate development of new therapies for challenging conditions driven or influenced by
complex biologic processes.
We are tackling the underlying mechanisms of chronic metabolic
diseases. Our goal is to develop treatments that align with real-world patient needs.
Globally, millions of patients lack effective treatment options. At the front end of Baerenkraft’s model is a proprietary AI-enabled discovery platform, which enables target identification in as little as 48 hours with a greater than 80% success in lead identification. This allows Baerenkraft to compress timelines from discovery to clinic to approximately 30 months, as compared to the industry average of 5–6 years.
Contact
We strive to exploit novel technologies combined with proven science to deliver powerful new therapies. Baerenkraft focuses on inflammation, immunology, and metabolic disorders, curating a pipeline of high-potential assets.
Pipeline
.svg)